Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Christopher Parker, Peter Hoskin et al.|The Lancet Oncology|2014Cited by 491